Our 28 Gy vs 24 Gy in 2 frx for spine SBRT out on pubmed. Dose escalation can increase local control but key is dose per fraction to keep VCF within acceptable limits. Congrats and thx to Sunnybrook Health Sciences Centre CNS team and my prior fellows and staff Dr. Eric Tseng pubmed.ncbi.nlm.nih.gov/36309076/

Happy to share our thoughts in the JCO on the randomized evidence on oligometastases, challenges in producing randomized evidence in this space, and ongoing phase III trials. Dr. David Palma, MD PhD Houda Bahig
ascopubs.org/doi/abs/10.120…

Spine SBRT: 28Gy vs 24Gy in 2 daily Fx
- Prospective DB: 482 pts, 947 segments
- Long median FU of 23.5 mo
👉 Reduced local failure in 28Gy cohort: 2a LF 11.1% vs 17.6%, sig. in MVA
👉 No increased rates of toxicity

👏 Contrats to arjun sahgal and team

redjournal.org/article/S0360-…

Shankar Siva Chad Tang, MD OncoAlert Piet Ost Peter Mac GU Oncology Arun Azad Thomas Zilli Jeff Bradley, MD MD Anderson Cancer Center ASTRO Alan Dal Pra, MD William A Hall, MD Daniel E Spratt Another confirmation of the power of Metastases-directed therapy in prostate cancer. ADT-free survival is patient-friendly endpoint Charlien Berghen Kato Rans steven joniau benedikt engels Karel Decaestecker #sbrt #prostatecancer #SABR #BRAVO

Late breaking abstracts #ASTRO22 - Chad Tang, MD EXTEND trial; oligometastatic #prostatecancer . Intermittent ADT + SABR versus ADR alone extends PFS, but importantly time men enjoy off ADT in the long term (eugonadal PFS). Important patient centric endpoint! 👏🏽⭐️ OncoAlert #pcsm

It was an honor to serve an ASTRO chair, and a pleasure to hand the gavel to Geraldine Jacobson. #womenwhocurie

The gavel has passed from one #WomenWhoCurie to another. Thank you Laura Dawson for your leadership this past year.

Late breaking #ASTRO22 - LUSTRE phase III N=233, randomised SABR vs conventional #radiotherapy in #lungcancer median F/U 3.1 yrs. BOTH central and peripheral tumours. Closed earlier than expected, no statistical diff between arms. So close!! 🫣 OncoAlert #radonc #lcsm

Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial

👉 Great that more studies are validating the ESTRO/EORTC OMD classification system !

redjournal.org/article/S0360-…

Proud to be among top recruiters of #oligomets 💪 for #oligocare study inside ESTRO !

Happy to announce that Ospedale Sacro Cuore Don Calabria in Negrar enrolled 200 patients in the OligoCare cohort of #E2RADIatE .

Thanks to the team and all patients! Filippo Alongi, @mat_guc Piet Ost ESTRO

👉 project.eortc.org/e2-radiate/

#SBRT #CancerResearch #ClinicalTrials

Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study jto.org/article/S1556-…

Laura Dawson NRG/RTOG 1112 phase III RCT, n=293. Median size 8.6cm. 22% in control arm crossover to SBRT at failure. ⬆️OS (HR0.77), still significant after MVA! Near double PFS, and no ⬆️ toxicity. All subgroups benefit. SABR is the new standard of care! 👏🏽👏🏽👏🏽🍾 #ASTRO22 OncoAlert

Piet Ost Shankar Siva Drew Moghanaki Henning Willers, MD (he/him/his) Peter Mac Radiation Oncology ASTRO Vedang Murthy Michael Chuong Memorial Sloan Kettering Cancer Center H. Jack West, MD Nathan A. Pennell MD, PhD, FASCO “High-risk” defined below 👇
Oligomet excluded

Primary endpoint: skeletal-related events (SRE)

OS secondary, not necessarily expected but has rationale to support and persisted on MVA

#ASTRO22

Erin Gillespie, MD presents a provocative phase II RCT of prophylactic #radiotherapy to asymptomatic but high risk bone Mets. N=93 Convincing home run, 29% vs 1.6% skeletal related events, with an ⬆️ OS benefit! Remained significant on MVA #ASTRO22 #OncoAlert

Ralph Weichselbaum Drew Moghanaki James Urbanic Matthias Guckenberger Jill Feldman Jim Pantelas Michel Itel Aadel Chaudhuri, MD PhD Jie Deng, MD PhD Sean Pitroda, M.D. Fiona McDonald Brendon Stiles Why so pessimistic? Here's where we stand so far:

Positive RCTs: Gomez, Iyengar, STOMP, ORIOLE, E40004, SABR-COMET, SINDAS (phase 3)

Negative RCTs: BR002, PulMiCC (which didn't accrue)

More phase 3s coming...we definitely have better odds than the Yankees! (or Blue Jays)

Engagiert für unsere Patient:innen - die Ärzt:innen der Klinik für Radio-Onkologie Unispital_USZ sind für sie da!
Prof. Guckenberger leitet ein Team von >20 Ärzt:innen, das jährlich über 2900 Behandlungsserien durchführt und Patient:innen mit hoher Kompetenz & Empathie betreut.

NRG Oncology/RTOG1205: Randomized phase II trial of concurrent Bevacizumab & Re-RT vs Bev alone for recurrent GBM
👉 median OS 10.1 vs 9.7 mo for BEV + RT vs BEV alone (HR=0.98)
👉 median PFS 7.1 vs 3.8 mo, HR=0.73, p= 0.05
👉 Re-RT well tolerated
❓ QoL
ascopubs.org/doi/abs/10.120…